文献速递慢性肾脏病肾血管病与高血压

FGF-2浓度与慢性肾脏病患者动脉粥样硬化进展的相关性

Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-03-08

该多中心前瞻性观察队列纳入481例CKD患者,用颈动脉和股动脉超声评估10个动脉区域的斑块,24个月后斑块区域增加定义为进展。基线70%有斑块,67%进展;进展者FGF-2较低(78 vs 98 pg/ml,P<0.01)。校正后FGF-2每升高50 pg/ml,进展风险降低(OR 0.86,95%CI 0.76-0.96)。

要点

  • CKD患者中基线FGF-2较高与24个月动脉粥样硬化进展风险较低独立相关。
  • FGF-2每升高50 pg/ml,进展风险OR 0.86(95%CI 0.76-0.96)。
  • FGF-2最低三分位组进展风险最高,最高三分位组调整OR 0.48(95%CI 0.28-0.82)。

核心结论

  • 低FGF-2水平与CKD患者动脉粥样硬化进展独立相关。

研究设计与样本

  • 多中心、前瞻性、观察性队列研究,纳入481例CKD患者。
  • 通过颈动脉和股动脉超声评估10个动脉区域斑块,24个月后斑块区域增加定义为进展。
  • 血浆FGF-2水平用multiplex分析测定,采用多变量logistic回归分析关联。

主要发现

  • 平均年龄61岁;CKD 3期占51%,4-5期占41%,透析占8%。
  • 基线335例(70%)有斑块;289例(67%)在24个月时动脉粥样硬化进展。
  • 基线有或无斑块者FGF-2水平相似(79 vs 88 pg/ml)。
  • 进展者FGF-2水平低于无进展者(78 vs 98 pg/ml;P<0.01)。
  • 校正后FGF-2每升高50 pg/ml,进展风险降低(OR 0.86;95%CI 0.76-0.96)。

关键数值与推荐

  • FGF-2三分位分析:最低三分位组102例进展(参照组)。
  • 中间三分位组86例进展,调整OR 0.70(95%CI 0.40-1.20)。
  • 最高三分位组74例进展,调整OR 0.48(95%CI 0.28-0.82)。

临床怎么用

  • 在CKD患者中,血浆FGF-2水平较低可能提示动脉粥样硬化进展风险较高。
  • FGF-2或可作为CKD患者动脉粥样硬化进展的风险评估生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. RESULTS: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4-5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). CONCLUSIONS: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bozic M, Betriu A, Bermudez-Lopez M, et al. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients. Clin J Am Soc Nephrol. 2018. PMID: 29519952. doi:10.2215/CJN.07980717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。